Oncology Times - Ot Broadcasts From The Ipad Archives

A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In this episode, journalist Peter Goodwin interviews study author D. Ross Camidge, MD, PhD, Director of Thoracic Oncology at the University of Colorado School of Medicine, on the recent findings.

Colleague Conversations offers insights into hematology/ oncology from two different perspectives: a seasoned hematologist/oncologist and an early-career clinician. In this installment, Oncology Times sat down with Christopher A. Jones, MD, MBA, HMDC, FAAHPM, and David Jonathan Casarett, MD, MA, FAAHPM, to discuss the relatively new field of palliative care. The discussion leads us through how the field has transformed oncology care, how palliative care physicians can address issues like racial disparities, and how telehealth is the wave of the future.

What’s in the OncTimesTalk, May 2021 Edition? New clinical findings on: Nivolumab in gastro-esophageal cancer, CDK4/6 inhibition for breast cancer, COVID-19 vaccination limitations, sitagliptin/graft-versus-host disease, breast cancer individualization, neo-adjuvant chemotherapy for rectal cancer. Featuring: Ronan Kelly (Austin TX), Erica Mayer (Boston MA), Sibylle Loibl (Frankfurt, Germany), Shabir Madhi (Johannesburg South Africa) and Thierry Conroy (Nancy, France). Interviews in this edition: Ronan J Kelly MD MBA, Baylor University Medical Center, Dallas Adjuvant Nivolumab “Practice Changing” in Resected Gastroesophageal Cancer Ronan Kelly tells OncTimesTalk about a big reduction in the risk of death, and doubling of median disease-free survival, from using nivolumab as adjuvant therapy for patients with esophageal, and gastro-esophageal junction, cancers after chemoradiotherapy plus surgery in the placebo-controlled phase-three CheckMate 577 study. https:/

Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. Today Dr. Bolwell revisits his Oncology Times column on “Values” and outlines how to grow from an individual-focused, emotion-based values system to living with more positive values.

In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.

Liam Holt, PhD, speaks in analogies when describing his work focusing on compression of cancer cells and how it affects their behavior and evolution at his lab at the Institute for Systems Genetics at NYU Grossman School of Medicine. The assistant professor in the Department Of Biochemistry and Molecular Pharmacology aims to characterize how compression of cells causes genome instability specifically in pancreatic cancer.

Oncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. In his recurring Oncology Times column Straight Talk: Today's Cancer Centers, Dr. Bolwell dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell discusses the art of forgiveness; including how to let it go when there is conflict and breach of trust.

Looking for insights on leadership? Listen to Brian J. Bolwell, MD, FACP, Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine, discuss his own leadership journey and lessons learned.

Naveen Pemmaraju, MD, discusses the therapeutic landscape of ultra-rare cancers as well as the importance of ongoing research in these patient populations. Additionally, he shares his own passion for this area of study and how it has shaped his career.

Muzaffar H. Qazilbash, MD, from The University of Texas MD Anderson Cancer Center, Houston, discusses what he loves about hematology/oncology, including patient interactions and lifelong learning.

Find out what intrigued HemOnc Times Editorial Advisory Board Member Pamela Crilley, DO, Cancer Treatment Center of America, Philadelphia, about working in hematology/oncology and why she is passionate about the profession.

HemOnc Times Editorial Advisory Board Member Margaret ‘Margie’ Kasner, MD, MSCE, of Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, shares her passion for the field of hematology/oncology as well as one of her most memorable patient experiences.

Andrew Zelenetz, MD, PhD, Chief of the Lymphoma Service and Vice Chair of Medical Informatics at Memorial Sloan Kettering Cancer Center, tells OT how oncologists there are training a computer to understand and compare big data sets… Here’s why he says that work will help cancer patients at MSKCC and beyond.

David E. Weissman, MD, founded the Palliative Care Center at the Medical College of Wisconsin, serves as Director of the Medical School Palliative Care Education Project, and is also Co-Director of the Center to Advance Palliative Care’s initiative to help oncs meet revised standards of care (Improving Palliative Care—Outpatients [OPAL-OP]). Listen to what he told OT are the trends in palliative care he sees in practice.

Alen Voskanian, MD—Innovation Advisor to the Centers for Medicare and Medicaid Services—describes the CMS project to test new payment and service delivery models. He shared with OT the key clinical implications for oncologists and the whole cancer care team.

Steven Wood, PhD, Healthgrades VP, explains the health care ratings company’s survey findings that reveal what cancer patients said were the top three most important factors in their treatment experiences.

Timothy Birdsall, ND, Chief Medical Information Officer at Cancer Treatment Centers of America, tells OT what goes into making the more than 300 chemotherapy order sets there. Listen to why he says it’s not easy…

Mikkael A. Sekeres, MD, MS—who’s co-chairing the unique initiative to bolster research for the rare disease—explains what’s on the agenda and who’s involved. Hear what he told OT about the $16-million, five-year plan.

Patricia A. Ganz, MD, explains why implementing standards for survivorship care is just as important as other patient education efforts on the cancer care trajectory. Hear what Ganz, coauthor of the IOM’s landmark Survivorship Report, told OT.

George W. Sledge, Jr., MD—a CancerLinQ Advisory Group member—explains how the rapid learning system will affect day-to-day oncology. Listen to what Sledge told OT Contributing Writer and “Practice Matters” blogger Lola Butcher.